APOC3 RNAi plozasiran lowers triglycerides; SHASTA-2

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
ACC.24 - Daniel Gaudet shares the results of the SHASTA-2 trial. The APOC3 RNAi plozasiran is highly effective and well tolerated in patients with severe hypertriglyceridemia, and demonstrated sustainability in the efficacy through week 48, according to Daniel Gaudet.
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Daniel Gaudet, MD, PhD is a clinician-researcher in lipidology and professor of medicine at the Université de Montreal (U de M), in Montreal, QC, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of SHASTA-2
Release date: 9 april 2024

Recommended

Details

Presenters

Overview
ACC.24 - Daniel Gaudet shares the results of the SHASTA-2 trial. The APOC3 RNAi plozasiran is highly effective and well tolerated in patients with severe hypertriglyceridemia, and demonstrated sustainability in the efficacy through week 48, according to Daniel Gaudet.
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Daniel Gaudet, MD, PhD is a clinician-researcher in lipidology and professor of medicine at the Université de Montreal (U de M), in Montreal, QC, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of SHASTA-2
Release date: 9 april 2024

More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia